Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection


ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Shareholders in AngioDynamics (NASDAQ:ANGO) are in the red if they invested a year ago

The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

AngioDynamics, (ANGO Investor Presentation - Slideshow

The following slide deck was published by AngioDynamics, Inc.

AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023

LATHAM, N.Y., March 13, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:00 a.m. ET the same da

AngioDynamics to Participate in Three Investor Conferences in March

LATHAM, N.Y., February 28, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:

Merit Medical: Reasonably-Priced Execution, With M&A Upside

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Is This Under-the-Radar Growth Stock a Buy?

Within that last group sits AngioDynamics (NASDAQ: ANGO), a little-known company that makes devices for treating peripheral vascular disease. Let's dig into AngioDynamics' fundamentals and valuation to address this question. With a market capitalization of just $539 million, AngioDynamics is a medtech business that flies under the radar of most retail investors.

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2023 Earnings Call Transcript January 5, 2023 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01. Operator: Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Second Quarter Earnings Call. At this time all participants are in listen-only-mode. A question-and-answer session will follow the formal presentation. As […]

AngioDynamics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

AngioDynamics ( NASDAQ:ANGO ) Second Quarter 2023 Results Key Financial Results Revenue: US$85.4m (up 9.1% from 2Q...

A Mostly Clean Quarter Drives A Better Valuation For AngioDynamics

AngioDynamics posted a pretty clean fiscal Q2 that was a little better than the sell-side expected. Click here to read our analysis of ANGO stock.